Jayesh Desai

Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

Silvia Stacchiotti, Anna Maria Frezza, Jean-Yves Blay, Elizabeth H Baldini, Sylvie Bonvalot, Judith VMG Bovee, Dario Callegaro, Paolo G Casali, RuRu Chun-ju Chiang, George D Demetri, Elisabeth G Demicco, Jayesh Desai, Mikael Eriksson, Hans Gelderblom, Suzanne George, Mrinal M Gounder, Alessandro Gronchi, Abha Gupta, Rick L Haas, Andrea Hayes-Jardon, et al.

Journal article  |  2021  |  CANCER

BACKGROUND: Among sarcomas, which are rare cancers, many types are exceedingly rare; however, a definition of ultra-rare cancers h..

BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?

Vanessa Wong, Margaret Lee, Rachel Wong, Jeanne Tie, Jeremy Shapiro, Jayesh Desai, Louise Nott, Simone Steel, Matthew Burge, Brigette Ma, Adnan Khattak, Wei Hong, Peter Gibbs

Journal article  |  2021  |  TARGETED ONCOLOGY

BACKGROUND: B-Raf proto-oncogene (BRAF)-V600E mutations (BRAFmt) in colorectal cancer (CRC) predominantly occur in right-side (RS)..

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar Garcia-Alfonso, Elena Elez, Ashwin Gollerkeri, Kati Maharry, Janna Christy-Bittel, Scott Kopetz

Journal article  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

PURPOSE: BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or..

A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours

Sunit Sarkar, Ben Tran, Lisa Horvath, Michael Lam, Peter Savas, Peter Grimison, James R Whittle, James C Kuo, Nicole Signal, David Edmonds, Philip Hogg, Danny Rischin, Jayesh Desai, Anne Hamilton

Journal article  |  2021  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

PURPOSE: This phase I study was conducted to evaluate the safety and Maximum Tolerated Dose of PENAO (4-(N-(S-penicillaminylacetyl..

Global BRAF testing practices in metastatic colorectal cancer.

Scott Kopetz, Axel Grothey, Fortunato Ciardiello, Jayesh Desai, Tae Won Kim, Tim Maughan, Eric Van Cutsem, Harpreet Singh Wasan, Rona Yaeger, Takayuki Yoshino, Ashwin Gollerkeri, Michelle Edwards, Montessa Rodriguez Lizaso, Josep Tabernero

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

128 Background:The BRAF V600E mutation is a marker of poor prognosis in patients with metastatic colorectal cancer (mCRC). Target..

Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.

Jayesh Desai, Marwan Fakih, Katrina Sophia Pedersen, Yong Sang Hong, Neil Howard Segal, Simon Allen, Lorna Bailey, Christelle Lenain, Danny Lu, Pakeeza Zahra Sayyed, Jochen Schulze, Michael Cecchini

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

82 Background: The MORPHEUS platform consists of multiple, global, open-label, randomized Phase Ib/II trials designed to identify..

The Role of Systemic Therapies in the Management of Soft Tissue Sarcoma

Nikki Burdett, Susie Bae, Anne Hamilton, Jayesh Desai

Book Chapter  |  2021

Recurrent SPECC1L-NTRK fusions in pediatric sarcoma and brain tumors

Dong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, Chelsea Mayoh, Alexandra Sexton-Oates, Amit Kumar, Mark Pinese, Sumanth Nagabushan, Loretta Lau, Louise E Ludlow, Andrew J Gifford, Michael Rodriguez, Jayesh Desai, Stephen B Fox, Michelle Haber, David S Ziegler, Jordan R Hansford, Glenn M Marshall, Mark J Cowley, Paul G Ekert

Journal article  |  2020  |  COLD SPRING HARBOR MOLECULAR CASE STUDIES

The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors h..

A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS

Paul Wood, Jayesh Desai, Kelly Waldeck, Jason Cain, Nick Gottardo, Robyn Strong, Kathryn Kinross, Michelle Carr, Janelle Jones, Lily Wong, David Ziegler, Jordan Hansford, Michael Michael, David Ashley

Conference Proceedings  |  2020  |  NEURO-ONCOLOGY

Abstract BACKGROUND Panobinostat treatment has been shown to terminally differ..

Long-term outcomes of pexidartinib in tenosynovial giant cell tumors

Hans Gelderblom, Andrew J Wagner, William D Tap, Emanuela Palmerini, Zev A Wainberg, Jayesh Desai, John H Healey, Michiel AJ van de Sande, Nicholas M Bernthal, Eric L Staals, Charles G Peterfy, Anna Maria Frezza, Henry H Hsu, Qiang Wang, Dale E Shuster, Silvia Stacchiotti

Journal article  |  2020  |  CANCER

BACKGROUND: The objective of this study was to report on the long-term effects of pexidartinib on tenosynovial giant cell tumor (T..